VMD — Viemed Healthcare, Inc.

Summary of Viemed Healthcare Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $78.1 million, up 24% year-over-year and 4% sequentially.
• Ventilator Rental Revenue: $36.4 million, an 8% increase from the prior year.
• Other Rental Revenue: $16.4 million, a 19% increase.
• Equipment Sales: Nearly doubled to $19 million, driven by sleep resupply and maternal health.
• Gross Profit: $45 million, representing 57.7% of revenue (down from 58.3% year-over-year).
• Net Income: $2.8 million ($0.07 per diluted share).
• Adjusted EBITDA: $13.7 million, margin of 17.6% (down from 22.7% year-over-year).
• Operating Cash Flow: $15.9 million; Free Cash Flow: $8.6 million.
• Net CapEx: $7.3 million (9.3% of revenue).
• Patient Count: 12,635 active ventilator patients, with a net addition of 546 patients during the quarter.

2. Strategic Updates and Business Highlights

• Viemed achieved record quarterly revenue and patient counts, with notable growth in ventilation and other service lines.
• The company successfully adapted to new CMS national coverage determination for home mechanical ventilation, resulting in increased patient onboarding.
• Growth in PAP setups and maternal health services, with maternal health showing significant sequential growth.
• A reorganization of the sales team was implemented to enhance leadership roles and improve market coverage.
• Investments were made in technology and operational capacity to support growth, including a new intake workflow partner that improved efficiency.

3. Forward Guidance and Outlook

• Full-year revenue guidance raised to $314 million to $320 million (previously $312 million to $320 million).
• Adjusted EBITDA guidance revised to $64 million to $68 million (previously $65 million to $69 million).
• Net CapEx outlook lowered to 8.5% to 10% of revenue (previously 9% to 10.5%).
• The company expects continued sequential growth in the second half of the year, with a target adjusted EBITDA margin of at least 20%.

4. Bad News, Challenges, or Points of Concern

• Adjusted EBITDA margin remains under pressure, primarily due to higher SG&A expenses growing faster than revenue.
• The gross margin decreased slightly year-over-year, influenced by revenue mix and increased distribution costs in maternal health.
• The company faces challenges in managing operational costs during its growth phase, including temporary duplications in costs due to transitioning operations.
• There is uncertainty regarding the capacity of respiratory therapists to manage the growing patient base effectively under the new NCD requirements.

5. Notable Q&A Insights

• The sales reorganization is expected to enhance the effectiveness of new sales representatives and improve patient onboarding.
• The increase in ventilator patient count is attributed to new orders, improved compliance, and better insurer approvals due to updated formulary rules.
• Maternal health is anticipated to grow at a faster rate than sleep resupply, with significant investments made to scale operations in both areas.
• Management acknowledged the need for ongoing improvements in compliance and patient retention, emphasizing their commitment to patient care and operational efficiency.

Overall, Viemed Healthcare demonstrated strong growth in Q2 2026, with strategic initiatives in place to support continued expansion, despite facing some operational challenges and margin pressures.